
RESPIRI LIMITED

DIRECTOR OPTIONS - UPDATE

On 20 December 2017 the Company announced the issue of 34,000,000 unlisted options. 12,000,000 of the unlisted options were to be issued to Mr Leon L'Huillier, the then Chairman of the Company.

On 6 July 2018 the Company announced that 14,000,000 of the 34,000,000 unlisted options had expired. Mr L'Huillier has advised that he is in dispute with the Company on the matter of the unlisted options. The Company rejects Mr L'Huillier's position.

The balance of the options, being 20,000,000 options approved by shareholders on 15 December 2017 at the Annual General Meeting, remain unvested and subject to the original terms and conditions approved by shareholders.

-End-

By Order of the Board

Julian Rockett
Company Secretary
+61 2 8016 2841

About Respiri Limited (ASX:RSH)

Respiri is a health technology company leading the way in the development of innovative devices and mobile health apps to improve the management of chronic and costly respiratory disorders such as asthma and COPD. Building on decades of experience in the research and development of cutting edge clinical products for hospitals, the company has first-mover advantage in providing broad access to its proprietary acoustic based clinical solutions for remote monitoring with the development of a suite of over-the-counter connected devices.

Health authorities universally agree that mHealth solutions can transform asthma care and health conscious consumers are rapidly embracing patient self-management with the aid of smartphones, the growth engine for Respiri's flagship product, AirSonea®. With the addition of new products, including a connected device for nocturnal monitoring in development, Respiri has a captive market, globally, of parents and carers of young children who cannot perform lung function tests. Respiri products have been cleared for use by the US Food and Drug Administration, the European Union CE, the Australian TGA and the commencement of an approval process for Asian markets has begun.

Respiri is especially proud of its recent de-risking of milestones. The substantial achievements over the past 18 months place Respiri in a lower risk position and on the cusp of commercialisation compared to the vast majority of medical device and biotech companies